Alvotech has grown revenue 92% a year over three years and 54% a year over five. Revenue growth, 3-year annual rate: +92% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: +54%, growth has picked up over the last three years. Years of annual history on file: 6, FY2020 to FY2025, as filed.

ALVOAlvotech

Healthcare

$5.79-27% 1Y

$5.79

$3.0052 weeks$8.98

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +20% year on year and operating margin widening (+653.7 points), but earnings down −111% year on year.

2 good, 1 to watch

Revenue trend+20% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Earnings trend−111% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+653.7 points operating

Trailing-twelve-month operating margin, 13.3% now against -640.3% a year earlier.

All from SEC EDGAR, as of Dec 31, 2025.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ALVO growing?

Alvotech has grown revenue 92% a year over three years and 54% a year over five.

+92%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · compounding fast · compounded from fiscal years as filed

Revenue growth, 5-year rate: +54%
Revenue growth, 5-year rate · +92% over three · growth has picked up over the last three years
Years of annual history on file: 6
Years of annual history on file · FY2020 to FY2025, as filed

Details›